Silence is the only listed RNAi player in Europe and a pioneer in this technology. Through the efforts of our skilled scientists over the years we have established a robust platform that allows us to effectively trigger RNAi in specific cell types. Our inventions are protected by a broad intellectual property estate, which is a fundamental asset. Together with our progress, the fact that the field is generally maturing means that RNAi drugs are close to becoming a powerful genetic medicine modality at the disposal of doctors and patients.
Full Year Results 2017Download
Full Year Results 2017298KB Download
Half Year Results 2017154KB Download
Full Year Results 2016898KB Download
Half Year Results 2016614KB Download
Full Year Results 20151MB Download
Annual Report 20172MB Download
Annual Report 20161MB Download
Annual Report 2015978KB Download
Annual Report 20149MB Download
Annual Report 2013928KB Download
Advanced GalNAc-siRNA Platform and Its Therapeutic Applications1MB Download
9th CTIP - Use of Advanced siRNAs Targeted to Hepatocytes for the Development of Novel Drugs to Treat Liver-related Disorders1MB Download
Oligo Oxford - Development of innovative hepatocyte-targeted siRNA conjugates for the treatment of liver-related disorders1MB Download
OPT Congress 2018 - Identification and Development of SLN1241MB Download
OPT Congress 2018 - Development of Novel Therapies Using GalNAc1MB Download
Our Corporate Governance framework is based on using the leadership provided by our Board to drive the effective execution of our strategy, ensuring that risk is appropriately mitigated and managed.
We have three Board Committees (Remuneration, Audit and Risk, and Nominations), focused on providing the required oversight to maintaining the highest Corporate Governance standards. Through these committees and regular interactions with the executive team, our Board applies internal financial controls and approves the Company’s policy and strategy.